Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 10/20 | 0.58 |
| ▸ | KIT | P10721 | 4/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | CTSC | P53634 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14805009 | 0.91 | EPHX2 (0.56) | EPHX2KITSYKDDR1TRPA1 | |
| SCHEMBL6922844 | 0.83 | EPHX2 (0.51) | EPHX2KITSYKDDR1 | |
| SCHEMBL14805004 | 0.79 | EPHX2 (0.46) | EPHX2KITSYKDDR1PDGFRA | |
| SCHEMBL6922978 | 0.79 | ABCG2 (0.49) | EPHX2 | |
| SCHEMBL6924128 | 0.76 | SYK (0.49) | EPHX2SYKLCK | |
| SCHEMBL6922975 | 0.76 | EPHX2 (0.49) | EPHX2TRPA1 | |
| SCHEMBL6924124 | 0.74 | EPHX2 (0.57) | EPHX2SYKDDR1CTSCSGMS2 | |
| SCHEMBL14805005 | 0.73 | TUBB4A (0.49) | EPHX2DDR1 | |
| SCHEMBL6923813 | 0.73 | EGFR (0.52) | EPHX2KITKDR | |
| SCHEMBL2769633 | 0.72 | EPHX2 (0.46) | EPHX2KITSGMS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916584-B2 | Benzisoxazoles and azabenzisoxazoles as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2014-12-23 | — | — | US | disclosed |
| US-20130079366-A1 | Benzisoxazoles and Azabenzisoxazoles as MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction | VANDERBILT UNIVERSITY (US) | 2013-03-28 | — | — | US | disclosed |
| WO-2011100614-A1 | BENZISOXAZOLES AND AZABENZISOXAZOLES AS mgluR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY (US) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079366-A1 | Benzisoxazoles and Azabenzisoxazoles as MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction | GRIK4, GRM4, GRIA4 | EPHX2 2498/4885KIT 4817/4885SYK 3831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.